SKILLMAN, N.J., Aug. 17 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today the publication of new data demonstrating positive clinical results achieved with the Engenex((R)) Advanced Negative Pressure Wound Therapy (NPWT) system.
The Engenex((R)) NPWT System, utilizing low pressure (75 mm Hg) and EasyRelease(TM) dressings incorporating Bio-Dome(TM) Interface Technology, is designed to safely and effectively promote the healing of difficult wounds.
The case series study, published in the June issue of the journal Ostomy Wound Management, evaluated use of the next generation NPWT system in the management of complex surgical and traumatic wounds. Following the application of the NPWT system in a protocol of care, all three cases showed a marked progression toward wound healing, with reduced wound volume and development of healthy granulated tissue. Clinicians also observed that the dressing - developed specifically for use with the Engenex((R) )NPWT system - was well tolerated, with no tissue growth into the dressing, "little to no" disturbance of the granulation bed during dressing changes, and "little to no" bleeding or trauma on removal of the dressing.
"As our experience and these cases suggest, we believe that the Engenex NPWT System, with its low pressure profile and unique, non-adherent dressings, may represent an advance in this technology, possibly benefiting wound and patient outcomes," said author Cheryl Nease, PT, Memorial Health Center in Savannah, GA.
In December 2008, ConvaTec signed a long-term global exclusive license agreement with Boehringer Technologies to market and distribute the Engenex((R)) NPWT System incorporating Bio-Dome(TM) Interface Technology. The Engenex((R)) NPWT System is an innovative technology and engineering solution that utilizes the application of negative pressure to a wound to promote healing by creating controlled tissue strain and removing excess fluid, including wound exudate. Every aspect of the System, from the wound interface to the user interface, has been designed to attain optimal clinical outcomes as well as a simplified application and monitoring system for patient care.
"This publication is just the beginning in the development of our clinical evidence base in support of this advanced NPWT technology," said Marcus Schabacker, Chief Scientific Officer, ConvaTec. "As the researcher noted, the acceptable levels of observed pain, exudate management, minimal bleeding and wound bed disruption are important factors for clinicians managing complex wounds and for the patients they care for - and validates the excellent response we have been receiving from our initial customers."
ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key business divisions - Ostomy Care, Wound Therapeutics, Continence and Critical Care and Infusion Devices - ConvaTec products support health care professionals from the hospital to the community health setting. From its headquarters in Skillman, New Jersey, the company oversees more than 8,000 employees in over 90 countries serving consumers and their health care professionals on six continents. For more information, please visit www.convatec.com.
Engenex is a registered trademark, and EasyRelease and Bio-Dome are trademarks of Boehringer Technologies L.P.
Our world is what we make of it is a trademark of ConvaTec Inc.
(C) 2009 ConvaTec Inc.
(1) Nease C. Using low pressure, negative pressure wound therapy for wound preparation and the management of split-thickness skin grafts in three patients with complex wounds. Ostomy Wound Management 2009;55(6)32-42.
Contacts Punnie Donohue ConvaTec 908-904-2151 email@example.com Courtney Judd Weber Shandwick 212-445-8365 firstname.lastname@example.org
Copyright©2009 PR Newswire.
All rights reserved